Three-year follow-up of accelerated transepithelial corneal cross-linking for progressive paediatric keratoconus. Issue 11 (12th February 2020)

• Record Type: Journal Article
• Authors: Tian, Mi; Jian, Weijun; Zhang, Xiaoyu; Sun, Ling; Zhou, Xingtao
• Is Part Of: British journal of ophthalmology. Volume 104:Issue 11(2020)
• Page Start: 1608
• Page End: 1612
• Publication Date: 2020-02-12
• Subjects: cornea; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2019-315260
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Purpose: To investigate the long-term safety and efficacy of accelerated transepithelial cornealcross-linking (ATE-CXL) in children with progressive keratoconus. Methods: Fifty-three eyes of 41 paediatric patients (34 boys, 7 girls; mean age 14.81±1.96 years) undergoing ATE-CXL were enrolled in the study. Corrected distance visual acuity (CDVA) and manifest refraction were assessed preoperatively and 36 months postoperatively. Corneal keratometry, corneal thickness and posterior elevation were measured using Pentacam preoperatively and 1, 6, 12 and 36 months postoperatively. Pachymetry and epithelial thicknesses were measured using optical coherence tomography preoperatively and 6, 12, and 36 months postoperatively. Results: Thirty-six months postoperatively, CDVA improved from 0.32±0.28 to 0.26±0.25 in logarithm of the minimum angle resolution (p=0.025). Maximum keratometry was 58.73±9.70 D preoperatively and 59.20±10.24, 58.28±9.33, 57.88±9.99 and 58.98±10.79 D at 1, 6, 12 and 36 months postoperatively throughout the 36-month follow-up period (p>0.05). Similarly, corneal central thickness, which was 492.42±33.83 µm postoperatively, also remained stable during the 36-month follow-up (p>0.05). Both posterior central elevation and posterior highest elevation were stable at 12 months after ATE-CXL (p>0.05), but increased at 36 months postprocedure (p<0.05). Corneal pachymetry and epithelial thicknesses remained stable throughout the follow-up period (p>0.05). Conclusions: ATE-CXL is a safe and effective treatment in paediatric progressive keratoconus patients, leading to stable keratometry and corneal thickness throughout the 36-month follow-up.